# Development of a Monocyte Activation Test for Evaluating Recombinant Hepatitis B Vaccine: A Novel Approach for Pyrogen Assessment

**Authors:** Delaram Doroud, Zohre Eftekhari, Mojtaba Daneshi, Parisa Gheibi, Nazanin Jabbari, Maryam Khatami, Marzieh Hosseini

PMC · DOI: 10.61186/ibj.4100 · Iranian Biomedical Journal · 2024-02-03

## TL;DR

Researchers developed a new test using monocytes to detect fever-inducing substances in a hepatitis B vaccine, showing it works better than traditional methods.

## Contribution

The study introduces a novel monocyte activation test (MAT) as a more sensitive alternative to traditional pyrogen tests for vaccine quality control.

## Key findings

- The MAT detected pyrogenic content at 2.5 EU/mL IL-6, more sensitive than the RPT's 5 EU/mL.
- Monocyte-derived IL-6 showed strong responses to LPS and LTA, suggesting its value as a pyrogen marker.
- The MAT proved consistent and accurate under European Pharmacopoeia standards, outperforming the RPT.

## Abstract

Injectable products, particularly human vaccines, must be free from fever-inducing agents and thoroughly tested for pyrogens as part of a quality control. Consequently, manufacturing facilities are required to conduct appropriate pyrogen tests per pharmacopoeial standards. This study aimed to evaluate the reliability of the MAT in quantifying pyrogenic content in the recombinant hepatitis B vaccine.

We assessed pyrogen activity in the API, formulated vaccine, and aluminum hydroxide by comparing the LAL, RPT, and MAT, measuring activity in RPU as per the European Pharmacopoeia. Monocytes from healthy donors were isolated and identified via flow cytometry to measure the CD14+ marker frequency.

The study found that the pyrogenic concentration of LTA in the MAT was 50,000 ng/mL (5.19 EEU/mL). In contrast, the same concentration in the RPT was deemed non-pyrogenic based on rectal temperature assessments. The MAT showed sensitivity to the API and adjuvant, with a detection limit of 2.5 EU/mL for IL-6, outperforming the RPT, which had a detection limit of 5 EU/mL.

A strong IL-6 response to both LPS and LTA stimulation was observed, indicating that IL-6 could serve as a valuable marker for pyrogen testing. The MAT appears to be an effective alternative to the RPT for assessing pyrogenicity, demonstrating commendable consistency and accuracy across various testing systems allowed by the Ph. Eur. General MAT Chapter, especially given the RPT's limitations in controlling pyrogenicity in injectable products.

## Linked entities

- **Chemicals:** aluminum hydroxide (PubChem CID 10176082), LTA (PubChem CID 71464637), IL-6 (PubChem CID 165368475)

## Full-text entities

- **Genes:** CD14 (CD14 molecule) [NCBI Gene 929], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** Hepatitis B (MESH:D006509), fever (MESH:D005334)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11829161/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11829161/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC11829161/full.md

---
Source: https://tomesphere.com/paper/PMC11829161